Complement 3 Is a Potential Biomarker for Cerebral Amyloid Angiopathy

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Cerebral amyloid angiopathy (CAA) is a cerebrovascular disease linked to Alzheimer's disease pathogenesis via amyloid-β deposition.
• Chronic neuroinflammation plays a significant role in both CAA and Alzheimer's disease.

Purpose of the Study:

• To investigate elevated circulating levels of complement 3 in patients diagnosed with cerebral amyloid angiopathy.
• To determine if complement 3, a key component of the innate immune system, is a potential biomarker for CAA.

Main Methods:

• Retrospective analysis of serum complement 3 levels using a sandwich enzyme-linked immunosorbent assay.
• Diagnosis of CAA based on modified Boston criteria in a cohort of mild cognitive impairment patients.
• Logistic regression analysis to identify predictive factors for cerebral amyloid angiopathy.

Main Results:

• Serum complement 3 levels were significantly higher in patients with CAA compared to those without.
• Increased complement 3 levels were independently associated with cerebral amyloid angiopathy.
• Complement 3 was identified as a significant independent predictive factor for CAA.

Conclusions:

• Complement activation appears to be crucial in the pathogenesis of cerebral amyloid angiopathy.
• Complement 3 shows potential as a novel diagnostic biomarker for identifying cerebral amyloid angiopathy.